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Abstract 
Purpose of the article  
Clozapine is the only evidence based treatment for treatmenrt-resistant schizophrenia. 
Constipation is a well known side effect of clozapine treatment that can progress to ileus, a 
potentially lethal outcome.  However, ileus has received much less attention than other adverse 
effects of clozapine, such as agranulocytosis.  The aims of this study are to describe the 
prevalence of constipation and ileus during clozapine treatment of patients with schizophrenia in 
Iceland and to assess the concomitant use of medication that can cause constipation and laxatives 
used to treat constipation.    
Materials and methods  
We identified 188 patients treated with clozapine by searching the electronic health records of 
Landspitali, the National University Hospital, during the study period 1.1.1998 – 21.11.2014.  
Cases of constipation and ileus were identified using an electronic search with keywords related 
to ileus in the patients’ electronic health records.  Detailed medication use was available for 154 
patients that used clozapine for at least one year. 
Results 
Four out of 188 patients were diagnosed with ileus that resulted in admission to hospital.  Two of 
these required a permanent stoma as a consequence of their ileus.  Laxatives were prescribed for 
24 out of 154 patients (15.4%) while on clozapine.  In total 40.9% of the patients either had 
laxatives prescribed or had constipation documented in the medical records.  Apart from 
clozapine, other medication known to cause constipation was prescribed by 28 out of 154 patients 
(18.2%). 
Conclusions 
Constipation is a common problem in clozapine treatment which can progress to full-blown ileus 
which can be fatal.  Clinicians need to monitor signs of constipation during treatment with 
clozapine and respond to it with lifestyle advice and laxative treatment.   
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Background 
Approximately 30% of patients with schizophrenia do not respond to conventional antipsychotics 
and are said to have treatment-resistant schizophrenia (1).  Those patients should be treated with 
clozapine, the only antipsychotic indicated for patients with treatment-resistant schizophrenia (2).  
Constipation is a very well known side effect of clozapine treatment.  A recent meta-analysis 
estimated the prevalence of clozapine-associated constipation to be 31.2% (3).  It is thought that 
the mechanism whereby clozapine causes constipation is through reduced gastrointestinal 
motility due to anticholinergic inhibition of gastrointestinal smooth muscle contractions (4).  
Serotonin antagonism may also compound the constipation problem (5).  Many patients with 
schizophrenia have sedentary lifestyles and low fiber diets which can exacerbate the risk for 
constipation (6).  Clozapine severely slows down the transit time through the gastrointestinal 
tract.  The median colonic transit time for patients clozapine has been shown to increase as much 
as fourfold, to be as high as 104 hours versus 23 hours in those never on clozapine (7).  The risk 
of constipation has resulted in very high usage of laxatives during clozapine treatment.  A UK 
study on outpatients reported that 35% of outpatients on clozapine used laxatives (8).  
Constipation can lead to ileus which can be fatal (9-11).  Few prevalence studies of ileus during 
clozapine treatment were identified in the literature.  The prevalence of ileus during clozapine 
treatment was reported to be 0.8% in a Danish study (11)  but only 0.1% in a large Chinese 
sample when studied in 1991 (12).  Ileus developing during antipsychotic treatment in Taiwan 
was, however, reported to have a 3.3% cumulative incidence rate, with patients on clozapine 
having the highest risk of all (13).   
Aims of the study 
The aims of the study were to describe the prevalence of constipation and ileus during clozapine 
treatment in patients with schizophrenia as well as to describe the use of laxatives and, apart from 
clozapine, other medication that can cause constipation among patients on antipsychotic 
treatment due to schizophrenia.      
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Materials and methods 
The study cohort has been described in a previous article by the authors (14).  Patients in the 
study were recruited from Landspitali University Hospital (LUH) Department of Psychiatry.  All 
611 patients who were participants in the study had a confirmed diagnosis of schizophrenia 
according to the “Schedules for Affective Disorder and Schizophrenia-Lifetime version” (SADS-
L) and were alive on 1.1.2003 (15). Patients using clozapine were identified using keyword 
search in the electronic health records for the text “clozapin”, “closapin” and “Leponex”.  
Medical notes with the clozapine keywords were reviewed to assess whether clozapine had been 
used and the time frame of use. In addition to electronic health records, paper medical records 
were reviewed for additional information.  In this way we identified 201 patients with 
schizophrenia who had used clozapine.   LUH started using electronic health records in 1998.  Of 
the 201 patients using clozapine there were 188 patients with sufficient medical data available 
during the study period and a documented use of clozapine after 1.1.1998.  The start of the follow 
up period was defined from 1.1.1998 or the start of clozapine treatment if it occurred later.  The 
end of the follow up period was defined as earliest date of following possible end points: the end 
of the study (21.11.2014), date of death if the patient had died, end of follow up date in LUH 
health records or the date of clozapine discontinuation if the patients had discontinued clozapine 
treatment.     
We assessed medication use as the last known medication regime in the medical notes 
before the end of follow-up or the date that the patient discontinued.  The time to maximum 
improvement achieved in positive symptoms may be as long as 6 months or more on clozapine 
treatment (16).  Dosing adjustments of clozapine can therefore take as long as a year and 
accordingly patients had to have been on clozapine for at least one year to be included in the 
study.  We had detailed medication information for 154 patients with schizophrenia and 145 out 
of them had been taking 100 mg or more of clozapine.  We looked for three classes of other 
medication, apart from clozapine, that are known to cause constipation.  We defined 
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anticholinergic as medication in the World Health Organization ATC class N04A***.  Opioids 
were defined as medication in the ATC class N02A*** and paracetamol-codeine combinations.  
Tricyclic antidepressants (TCA) were defined as amitriptyline, nortriptyline, imipramine, 
clomipramine and doxepin.   
A keyword search in the electronic health records was done to find medical notes that 
called for further assessments of constipation and ileus.  The keywords used were: “hægð“  
“hægðatr”, “stíflaður”, “stífluð”, “constip”, “obstip”, “ileus”, “intestinal”, “garnastífla”, “Stoma”,  
“stoma”, “garnalömun”.  All medical notes found in the electronic searches were reviewed and 
assessed if the patient had, in the electronic health records, been reported to have developed 
constipation or ileus during clozapine treatment.  Ileus was defined as a severe obstruction of the 
gastrointestinal tract that resulted in an admission to a LUH somatic department and required 
treatment.  Constipation was rated if the patient had a documented complaint of constipation in 
the electronic health records during clozapine treatment or if he was treated with laxatives in the 
last known medication regime while on clozapine.   
All participants gave written informed consent.  The study was reviewed and approved by the 
Icelandic National Bioethics Committee (FS-02-041(03–030)) and the Data Protection Authority 
(2009090737ÞS). 
 
  
Commented [MJ1]: How could they give consent if it was a 
record linkage study? In the UK and most coutries, consent is not 
required for such studies as long as personal data are not reported – 
presumably the same applies in Iceland? 
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Results 
The mean observational period during clozapine treatment for the 188 patients ever on clozapine 
was 8.9 years and median time was 9.3 years.  The mean age at the end of follow up was 50 
years.  Four patients out of 188 (2.1%) were diagnosed with ileus with no tumor detected.  The 
estimated ileus incidence rate was therefore 2.4 cases per 1000 person years.  Two of the four 
patients developing ileus required ileostomy surgery that resulted in a permanent stoma.  The 
mean time from the onset of clozapine treatment to ileus was 13.7 years (15.3, 8.7, 17.6 and 13.3 
respectively).  The mean age at the time of ileus was 50.6 years (47.4, 54.4, 66.5 and 34.0).  No 
fatalities were associated with ileus.  Three out of these four patients continued on clozapine 
treatment after being diagnosed with ileus while one patient discontinued clozapine treatment 
shortly after developing ileus but this patient recommenced the clozapine treatment half a year 
later.   
There were 28 patients out of 154 (18.2%) participants on clozapine that used other 
medication which are known to reduce bowel movements (anticholinergics, TCA and opioids).  
Of them biperiden was the most common medication, 21 patients using it.  Four patients were on 
amitriptyline, two on tramadol, two on morphine and one on codeine-paracetamol combination.  
Of the 28 patients on clozapine as well as some other medication associated with constipation 
only half were receiving laxatives.  Of the four patients diagnosed with ileus, three were taking 
biperiden (an anticholinergic) and two out of four were on laxatives.    
Laxatives were prescribed by 24 patients out of 154 (15.6%).  Five patients were 
prescribed more than one laxative while on clozapine.  The laxatives used were sorbitol (n = 9), 
senna glycosides (n = 7), magnesium hydroxide (n = 6), sodium picosulfate (n = 5), Semen psyllii 
(n = 3) and bisacodyl (n = 2).  Of the 154 patients, more than one in three, 55 (35.7%), had 
constipation documented in their health records.  When defining constipation as being present for 
those patients that either had a documented constipation problem in the health records or were 
prescribed laxatives then 63 patients out of 154 (40.9%) had constipation.  The mean clozapine 
Commented [MJ2]: I am not familiar with that name. Either we 
do not have it or we call it by a different name. Is that the trade name 
or a generic name? 
Commented [MJ3]: Another one i haven’t heard of – I’ve heard 
of semen but not as a laxative! 
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dose for patients with constipation defined in this way was 328 mg versus 284 mg for patients 
that did not have constipation but the difference fell just short of statistical significance (p = 
0.06).    
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Conclusion  
The observed prevalence of ileus in the cohort was 2.1% which is higher than previously reported 
in Denmark (0.8%) (11) and much higher than in China (0.1%), the latter difference may be 
partially explained of course by differences in diet and lifestyle (12).  The higher incidence we 
observed compared to the Danish study might be explained with a longer observation period but 
ileus can occur anytime during clozapine treatment as was evident in our sample where the mean 
time to ileus was 13.7 years versus 4.2 years in Denmark (11).  The incidence rate was 2.4 cases 
per 1000 person years which was though lower than in Taiwan where it was observed to be 4.4 in 
patients with schizophrenia on any antipsychotic, the association being though strongest with 
clozapine (13).   This continuous risk of ileus is different than with agranulocytosis where around 
80% of the overall risk is present during the first half year of treatment but only 20% remain as 
the cumulative risk in due course during long-term treatment (17, 18).  The prevalence of ileus in 
this study is higher than the prevalence of agranulocytosis in Iceland and in other larger studies 
where the prevalence has been reported to be 0.7% (17-19).  The case fatality in ileus has been 
reported be in the range from 7.3% - 27.5% (9-11) versus 3% in agranulocytosis (20, 21) so 
physicians should be at least as vigilant with regard to constipation and the development of ileus 
as they are with neutropenia and the possible development of agranulocytosis.  The use of 
laxatives was low in our sample with only 15.6% of patients using laxatives compared to 35% in 
a UK sample (8).  This suggests that laxatives may be underused in Iceland for these patients.  
There were up to six different laxatives prescribed in the cohort for constipated patients on 
clozapine. This may reflect lack of evidence as to which laxative have most efficacy in the 
treatment of constipation during clozapine treatment (22).   
There are some limitations in our dataset.  The prevalence of constipation may be 
underestimated if some patients raised their complaints about constipation only in primary care 
but not at LUH since we did not have access to the primary care records to do an electronic health 
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record search.  It is also possible that some patients may have received off-label laxatives not 
recorded in the medical prescription charts.   
Physicians must pay close attention to signs of constipation in these patients and respond 
promptly both with lifestyle advice, including dietary advice, and treat it with laxatives as well.  
Laxatives appear to be under-prescribed for patients on clozapine treatment in Iceland.  Given the 
high prevalence rates of constipation during clozapine treatment it may be beneficial to start all 
patients on clozapine on preventive measures, even laxatives, especially those who are also 
receiving other medication that are associated with constipation.  
Síða 11 af 15 
Acknowledgements 
We thank Georg Vougiouklakis, Harpa Rúnarsdóttir, Sigurlaug J. Sigurðardóttir, Hrönn Scheving 
Guðmundsdóttir and Vilborg Kristín Gísladóttir for assistance in retrieving additional patient 
data,  Þuríður Þórðardóttir and Ingibjörg Richter for assistance with databases, and members of 
the CRESTAR consortium. 
Disclosure statement 
The authors report no conflicts of interest. The authors alone are responsible for the content and 
writing of the paper. 
Biographical note  
Oddur Ingimarsson is a consultant psychiatrist working at Landspitali University Hospital 
specialized inpatient rehabilitation unit at Kleppur where most patients have schizophrenia, 
substance abuse disorders and are involuntarily committed.  Oddur submitted his Phd thesis in 
November 2017. His research in the thesis focuses on the descriptive epidemiology of clozapine 
use in schizophrenia in Iceland and serious adverse-drug reactions to clozapine, including 
agranulocytosis and type 2 diabetes.   
Engilbert Sigurðsson is a consultant psychiatrist and professor of psychiatry and Landspitali and 
the University of Iceland where he currently serves as the Dean of the Faculty of Medicine. 
Funding information 
This project has received funding from the European Union’s Seventh Framework Programme 
for research, technological development and demonstration under grant agreement no. 279227, 
and from the Science Fund of Landspitali – The National University Hospital of Iceland. Dr 
MacCabe is part funded by the National Institute for Health Research (NIHR) Biomedical 
Research Centre at South London and Maudsley NHS Foundation Trust and King’s College 
London. The views expressed are those of the authors and not necessarily those of the NHS, the 
NIHR or the Department of Health. 
 
Síða 12 af 15 
 
 
 
  
Síða 13 af 15 
References 
1. Meltzer HY. Treatment-resistant schizophrenia--the role of clozapine. Curr Med Res 
Opin. 1997;14(1):1-20. 
2. Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Comparative Effectiveness of 
Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. Am J 
Psychiatry. 2016;173(2):166-73. 
3. Shirazi A, Stubbs B, Gomez L, Moore S, Gaughran F, Flanagan RJ, et al. Prevalence and 
Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis. Int J 
Mol Sci. 2016;17(6). 
4. Ozbilen M, Adams CE. Systematic overview of Cochrane reviews for anticholinergic 
effects of antipsychotic drugs. J Clin Psychopharmacol. 2009;29(2):141-6. 
5. Crowell MD. The role of serotonin in the pathophysiology of irritable bowel syndrome. 
Am J Manag Care. 2001;7(8 Suppl):S252-60. 
6. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with 
schizophrenia. Psychol Med. 1999;29(3):697-701. 
7. Every-Palmer S, Nowitz M, Stanley J, Grant E, Huthwaite M, Dunn H, et al. Clozapine-
treated Patients Have Marked Gastrointestinal Hypomotility, the Probable Basis of Life-
threatening Gastrointestinal Complications: A Cross Sectional Study. EBioMedicine. 
2016;5:125-34. 
8. Bailey L, Varma S, Ahmad N, Gee S, Taylor DM. Factors predicting use of laxatives in 
outpatients stabilized on clozapine. Ther Adv Psychopharmacol. 2015;5(5):256-62. 
9. Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-
induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry. 
2008;69(5):759-68. 
Síða 14 af 15 
10. Every-Palmer S, Ellis PM. Clozapine-Induced Gastrointestinal Hypomotility: A 22-Year 
Bi-National Pharmacovigilance Study of Serious or Fatal 'Slow Gut' Reactions, and Comparison 
with International Drug Safety Advice. CNS Drugs. 2017;31(8):699-709. 
11. Nielsen J, Meyer JM. Risk factors for ileus in patients with schizophrenia. Schizophr Bull. 
2012;38(3):592-8. 
12. Lu MK. [Clinical analysis in the main side effects of clozapine: enclosed 600 cases 
report]. Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1991;24(2):71-4, 123. 
13. Chen HK, Hsieh CJ. Risk of gastrointestinal Hypomotility in schizophrenia and 
schizoaffective disorder treated with antipsychotics: A retrospective cohort study. Schizophr Res. 
2017. 
14. Ingimarsson O, MacCabe JH, Haraldsson M, Jónsdóttir H, Sigurdsson E. Risk of diabetes 
and dyslipidemia during clozapine and other antipsychotic drug treatment of schizophrenia in 
Iceland. Nord J Psychiatry. 2017;71(7):496-502. 
15. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and 
schizophrenia. Arch Gen Psychiatry. 1978;35(7):837-44. 
16. Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin 
Schizophr Relat Psychoses. 2012;6(3):134-44. 
17. Schulte P. Risk of clozapine-associated agranulocytosis and mandatory white blood cell 
monitoring. Ann Pharmacother. 2006;40(4):683-8. 
18. Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring 
of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J 
Psychiatry. 1999;175:576-80. 
19. Ingimarsson O, MacCabe JH, Haraldsson M, Jónsdóttir H, Sigurdsson E. Clozapine 
treatment and discontinuation in Iceland: A national longitudinal study using electronic patient 
records. Nord J Psychiatry. 2016;70(6):450-5. 
Síða 15 af 15 
20. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced 
agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162-
7. 
21. Lahdelma L, Appelberg B. Clozapine-induced agranulocytosis in Finland, 1982-2007: 
long-term monitoring of patients is still warranted. J Clin Psychiatry. 2012;73(6):837-42. 
22. Every-Palmer S, Newton-Howes G, Clarke MJ. Pharmacological treatment for 
antipsychotic-related constipation. Cochrane Database Syst Rev. 2017;1:CD011128. 
 
 
